4Wunderink RG, Waterer GW. Clinical practice Community -ac- quired pneumonia[J]. N Engl J Med, 2014, 370(6) : 543 - 551.
5Brown AO, Millett ER, Quint JK, et al. Cardiotoxicity during in- vasive pneumoeoeeal disease [ J ]. Am J Respir Crit Care Med, 2015, 191(7) : 739 -745.
6Dumke R, Schnee C, Pletz MW, et al. Mycoplasma pneumoniae and Chlamydia spp. Infection in community -acquired pneumonia, Germany, 2011 -2012[J]. Emerg Infect Dis, 2015, 21 (3): 426 - 434.
7Zhao F, Liu G, Wu J, Cao B, et al. Surveillance of maerolide - resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012 [ J ]. Antimierob Agents Chemother, 2013, 57 ( 3 ) : 1521 - 1523.
8Cao B, Zhao C J, )in YD, et al. High prevalence of macrelide resistance in Mycoplasma pneumoniae isolates from adult and ado- lescent patients with respiratory tract infection in China[ J ]. Clin Infect Dis, 2010, 51(2) : 189 -94.
9Ishiguro T, Takayanagi N, Yamaguchi S, et al. Etiology and fac- tots contributing to the severity and mortality of community - ac- quired pneumonia [ J ]. Intern Med, 2013, 52 ( 3 ) : 317 - 324.
10Bjarnason A, Asgeirsson H, Baldursson O, et al. Mortality in healthcare- associated pneumonia in a low resistance setting: a prospective observational study [ J ]. Infect Dis ( Lond ), 2015, 47(3) : 130-136.
